Diversified Trust Co Buys Shares of 7,016 Hologic, Inc. (NASDAQ:HOLX)

Diversified Trust Co purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 7,016 shares of the medical equipment provider's stock, valued at approximately $506,000.

Other large investors have also recently made changes to their positions in the company. Wolff Wiese Magana LLC purchased a new stake in Hologic during the third quarter worth about $25,000. General Partner Inc. purchased a new stake in Hologic during the 4th quarter worth approximately $26,000. Groupama Asset Managment increased its stake in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares during the period. Sunbelt Securities Inc. purchased a new position in Hologic in the 2nd quarter valued at approximately $37,000. Finally, First Horizon Advisors Inc. boosted its position in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.75% of the stock is owned by company insiders.

Hologic Stock Performance

Shares of HOLX stock traded down $1.04 during mid-day trading on Friday, hitting $71.70. 2,147,897 shares of the stock were exchanged, compared to its average volume of 1,978,683. The stock's fifty day simple moving average is $75.88 and its two-hundred day simple moving average is $78.51. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 12-month low of $70.36 and a 12-month high of $84.67. The stock has a market capitalization of $16.27 billion, a price-to-earnings ratio of 21.53, a P/E/G ratio of 2.32 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.89 EPS. On average, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on HOLX shares. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 price objective on shares of Hologic in a research note on Thursday, December 19th. Leerink Partners reduced their price target on Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Citigroup downgraded Hologic from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Wolfe Research initiated coverage on shares of Hologic in a report on Friday, December 13th. They issued a "peer perform" rating on the stock. Finally, Royal Bank of Canada boosted their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a report on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $89.50.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.